Flagship Pioneering is on record against 36 companies.
We invest at the proto-company and new-company stages, scaling into growth companies. Our focus is on bioplatforms with proprietary discovery engines and in-house drug development, with a geographic emphasis on partnerships including Pfizer and Novo Nordisk.